Safety by Design for Cytotoxic Tabletting
Gamlen Tableting will be launching the GTP-SafeTab at AAPS 2014. The GTP-SafeTab incorporates an innovative containment solution to enable the use of a Gamlen Tablet Press with cytotoxic and other highly-potent APIs.
With space to enable the operator to use a Gamlen Tablet Press along with other equipment, the GTP-SafeTab system is a completely self-contained environment designed precisely for cytotoxic work.
Michael Gamlen, Managing Director, explains: "When handling biologically reactive materials you must protect the operator. Normally you would use a fume cupboard or a biological cabinet. Gamlen Tableting has developed a HEPA filtered semi-disposable cabinet system that can be used anywhere, providing a flexible and economical alternative to retrofitting containment solutions on existing equipment.
The Gamlen Tablet Press is ideal for cytotoxic work as it has few components and crevices to entrap material and allows early analysis and assessment of material properties using tiny amounts of material to reduce waste, save time and money.
The GTP-SafeTab will be launched at AAPS 2014 in San Diego, 2-6 November at booth #3612. Entirely computer controlled, the GTP is a portable laboratory machine that can be used to discover more about tablets and tableting conditions including: compaction, compression, ejection force, hardness, lubricity, tensile fracture stress and humidity effects.
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.